Holger Neecke is Director of Business Development at Adare Pharmaceuticals in Milan, a specialty CDMO business science-driven provider of dosage form solutions for the healthcare industry. He joined Adare Pharmaceuticals in 2015.
Before joining Adare, he held BD positions in MolMed SpA (cell and gene therapy) and Ablynx NV (antibody fragments).
Holger Neecke negotiated and closed numerous agreements with biotech and pharma companies in the EU, the US and Japan ranging from early stage R&D collaborations to marketed products and comprising small molecules, biologics and cell and gene therapy products.
Holger Neecke holds a degree in Molecular Biology from the University of Basel, Switzerland, a PhD in Genetics from the University of Milan, and a MBA from SDA Bocconi Business School, Milan.